Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02065310 · ClinicalTrials.gov registry record · NA
N2-(1-carboxyethyl)-2'Deoxyguanosine (CEdG) a Potential Biomarker for Diabetes
A NA study of Diabetes, sponsored by City of Hope Medical Center.
- Completed
- Registry status
- NA
- Development phase
- 26
- Enrollment target
- 1
- Study location
NCT02065310: Completed NA study of Diabetes, sponsored by City of Hope Medical Center.
NCT02065310 is a NA study of Diabetes that has completed, run by City of Hope Medical Center. The registered enrollment target is 26 participants, below the 3,028-participant average among 338 other Diabetes trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02065310, a NA study of Diabetes, has completed, sponsored by City of Hope Medical Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 26 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to see if the CEdG assay can produce internally consistent results and initiate its validation as a biomarker for diabetes in humans.
Conditions Studied
Interventions
- OTHER N2-(1-carboxyethyl)-2'deoxyguanosine (CEdG)
Study Locations (1)
California
- City of Hope Medical Center - Duarte
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2014-10 |
| Est. Completion | 2019-02-11 |
| Phase | NA |
What the finished NCT02065310 record still lists
NCT02065310 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 26 participants, a relatively small participant target, below the 3,028-participant average among 338 other Diabetes trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Diabetes appearing as the primary indexed condition, and to 1 intervention - of which N2-(1-carboxyethyl)-2'deoxyguanosine (CEdG) is the first listed.
NCT02065310 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT02065310 about?
NCT02065310 is a clinical study titled "N2-(1-carboxyethyl)-2'Deoxyguanosine (CEdG) a Potential Biomarker for Diabetes". The purpose of this study is to see if the CEdG assay can produce internally consistent results and initiate its validation as a biomarker for diabetes in humans.
What is the current status of trial NCT02065310?
This trial is currently completed. It is a NA study. The enrollment target is 26 participants. The study started on 2014-10. Estimated completion is 2019-02-11.
What conditions does trial NCT02065310 study?
This clinical trial studies the following conditions: Diabetes.
What interventions are being tested in trial NCT02065310?
The interventions under investigation include: N2-(1-carboxyethyl)-2'deoxyguanosine (CEdG) (OTHER).
Who is sponsoring clinical trial NCT02065310?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02065310 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02065310's enrollment target sits among peer trials
26 292nd of 338 higher than 46 of 338 other Diabetes trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Effect of 2-Week Continuous Glucose Monitoring on Glycemic Management in Patients New-to-Insulin on Hospital Discharge
RECRUITING · NA
-
Effects of Whole vs. Nonfat Milk Consumption on Body Composition in Children
RECRUITING · NA
-
Efficacy of Viome's Precision Nutrition Program Towards Reducing HbA1c
RECRUITING · NA
-
Targeting Metabolic Syndrome From the Emergency Department Through Mixed-Methods: Pilot Trial
RECRUITING · NA
-
Maturation of Arteriovenous Fistula With Automated Sonography Assessments Trial
RECRUITING · NA
-
Bringing Advocacy Via Digital Guide to the Emergency Department (Project BADGE)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02646475 · 26 participants · Phase 1
Metabolic Effects of Angiotensin-(1-7)
- NCT03603223 · 26 participants · Phase 2
Pembrolizumab in Treating Participants With Leukoplakia
- NCT04063592 · 26 participants · NA
AMI Construction in Lower Extremity Residual Limbs
- NCT04906460 · 26 participants · Phase 1
Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia